SAN DIEGO, April 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb) combined with XELOX (capecitabine plus oxaliplatin) as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (AK104-302/COMPASSION-15) were released presented in the form of oral presentation at the 2024 American Association for Cancer Research (AACR).
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved...
Akeso`s bispecific notches ph. 3 victory against gastric cancer
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
Although the addition of trifluridine/tipiracil (TAS-102; Lonsurf) to bevacizumab (Avastin) in the first line did not produce superior survival benefit vs standard capecitabine (Xeloda) and bevacizumab, similar efficacy results between both arms indicate that the regimen may still be a viable treatment for patients with unresectable metastatic colorectal cancer (mCRC) who are ineligible for intensive chemotherapy, according to Thierry André, MD.
Although adjuvant treatment with ibandronate (Boniva) plus capecitabine resulted in a numerical improvement in overall survival (OS) vs ibandronate alone in elderly patients with moderate or high-risk early breast cancer, this did not reach statistical significance, according to long-term data from the phase 3 ICE study (GBG 32, BIG 4-04; NCT00196859).
Intas Pharmaceuticals Limited on FDA Import Alert List
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a clinical stage oncology company, today presented results from a Phase 1 study with CYT-0851 in combination with capecitabine or gemcitabine in a poster titled “Phase 1 Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors” (Abstract: 3099, Poster: 297) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois.
Several biotechs are looking to make changes to their pipelines as the quarter has drawn to a close.
SHANGHAI, May 5, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that AB011 in combination with atezolizumab monoclonal antibody, Roche's PD-L1 checkpoint inhibitor, along with chemotherapy (capecitabine and oxaliplatin) achieved IND clearance from the CDE for first-line treatment Claudin18.2 (CLDN18.2) positive unresectable locally advanced, recurrent or metastatic gastric cancer/gastroesophageal junction cancer.